MaxCyte, Inc. (NASDAQ:MXCT) Director Sells $11,160.00 in Stock

MaxCyte, Inc. (NASDAQ:MXCT) Director John Joseph Johnston sold 3,000 shares of MaxCyte stock in a transaction on Monday, October 28th. The shares were sold at an average price of $3.72, for a total transaction of $11,160.00. Following the completion of the sale, the director now owns 141,950 shares in the company, valued at approximately $528,054. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

John Joseph Johnston also recently made the following trade(s):

• On Thursday, September 26th, John Joseph Johnston sold 3,000 shares of MaxCyte stock. The stock was sold at an average price of $3.82, for a total transaction of $11,460.00.
• On Monday, August 26th, John Joseph Johnston sold 3,000 shares of MaxCyte stock. The shares were sold at an average price of $4.28, for a total transaction of $12,840.00.

MaxCyte Trading Down 0.8 %

MaxCyte stock traded down $0.03 during trading hours on Wednesday, hitting $3.54. 279,457 shares of the stock traded hands, compared to its average volume of 507,705. MaxCyte, Inc. has a one year low of $2.92 and a one year high of $5.55. The company has a market cap of $372.30 million, a PE ratio of -10.50 and a beta of 1.39. The firm’s 50-day moving average price is $3.93 and its two-hundred day moving average price is $4.19.

MaxCyte (NASDAQ:MXCT) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.05. The company had revenue of $10.43 million for the quarter, compared to analyst estimates of $8.20 million. MaxCyte had a negative return on equity of 15.52% and a negative net margin of 77.97%. During the same period in the previous year, the company posted ($0.10) earnings per share. On average, sell-side analysts expect that MaxCyte, Inc. will post -0.44 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Russell Investments Group Ltd. bought a new stake in MaxCyte during the first quarter worth about $28,000. PNC Financial Services Group Inc. bought a new stake in shares of MaxCyte in the 4th quarter worth approximately $29,000. China Universal Asset Management Co. Ltd. grew its stake in shares of MaxCyte by 64.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 20,212 shares of the company’s stock worth $79,000 after buying an additional 7,930 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in MaxCyte by 20.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 25,199 shares of the company’s stock valued at $106,000 after buying an additional 4,320 shares in the last quarter. Finally, Creative Planning raised its stake in MaxCyte by 33.6% during the third quarter. Creative Planning now owns 28,652 shares of the company’s stock valued at $111,000 after buying an additional 7,212 shares during the last quarter. 68.81% of the stock is currently owned by institutional investors.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.